Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Lai YKY, Shen WY, Brankov M, Lain CM, Constable IJ, Rakoczy PE . Gene Therapy 2002;9:804-813. Dr. Y.K.Y. Lai, Department of Molecular Ophthalmology/Lions Eye Institute, 2 Verdun Street, Nedlands 6009, Western Australia, Australia

Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Lai YKY, Shen WY, Brankov M, Lain CM, Constable IJ, Rakoczy PE . Gene Therapy 2002;9:804-813. Dr. Y.K.Y. Lai, Department of Molecular Ophthalmology/Lions Eye Institute, 2 Verdun Street, Nedlands 6009, Western Australia, Australia

To achieve stable and localized ocular anti-angiogenic therapy, the authors used recombinant adeno-associated virus (rAAV)-mediated secretion gene therapy (SGT).

Saved in:
Bibliographic Details
Published in:American journal of ophthalmology Vol. 135; no. 1; p. 127
Format: Journal Article
Language:English
Published: Chicago Elsevier Limited 01-01-2003
Subjects:
Gene therapy
Rodents
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To achieve stable and localized ocular anti-angiogenic therapy, the authors used recombinant adeno-associated virus (rAAV)-mediated secretion gene therapy (SGT).
ISSN:0002-9394
1879-1891
DOI:10.1016/S0002-9394(02)02041-X